Trial Profile
Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- Acronyms ProsPERo
- 22 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Jan 2017 Planned initiation date changed from 1 Sep 2016 to 1 Jun 2017.
- 06 Sep 2016 Study phase has been changed from phase III to phase II.